These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

887 related items for PubMed ID: 14500805

  • 21. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP.
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG.
    N Engl J Med; 2014 Jan 30; 370(5):412-20. PubMed ID: 24382002
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD, Farahmand P, Schacht E, Rozehnal A.
    Rheumatol Int; 2007 Mar 30; 27(5):425-34. PubMed ID: 17216477
    [Abstract] [Full Text] [Related]

  • 27. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.
    J Clin Endocrinol Metab; 2015 Feb 30; 100(2):697-706. PubMed ID: 25393645
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study.
    Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M, Gennari L, Gennari C, Nuti R.
    Calcif Tissue Int; 2003 Aug 30; 73(2):133-9. PubMed ID: 14565594
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT, Christensen PM, Ejersted C, Langdahl BL.
    Basic Clin Pharmacol Toxicol; 2004 Jun 30; 94(6):260-70. PubMed ID: 15228497
    [Abstract] [Full Text] [Related]

  • 33. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 30; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 34. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, Tan SS, Tsou IY, Tan SH.
    Arch Dermatol; 2012 Mar 30; 148(3):307-14. PubMed ID: 22105813
    [Abstract] [Full Text] [Related]

  • 35. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
    Greenspan SL, Holland S, Maitland-Ramsey L, Poku M, Freeman A, Yuan W, Kher U, Gertz B.
    Proc Assoc Am Physicians; 1996 May 30; 108(3):230-8. PubMed ID: 8774056
    [Abstract] [Full Text] [Related]

  • 36. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep 30; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Yonsei Med J; 2004 Aug 31; 45(4):676-82. PubMed ID: 15344210
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.